Adult Failure to Thrive and Debility Can No Longer Be Principal Diagnoses on Hospice Claim Forms

by Baker Donelson
Contact

This article originally appeared in the November 2013 issue of LTC-SIR Advisor Newsletter, published by the American Health Lawyers Association.

Hospices will have until October 1, 2014, to ensure they conform their coding practices to comply with a “clarification” issued by the Centers for Medicare and Medicaid Services (CMS) in its final FY2014 Hospice Wage Index and Payment Rate Update, published in the Fed. Reg. on August 7, 2013.1   CMS’s policy, as clarified, is that the ICD-9 codes for “adult failure to thrive” and “debility” are not to be used as principal diagnoses on the hospice Medicare claim form when a related definitive diagnosis has been established or confirmed by the provider. Any claims submitted after October 1, 2014 that have debility or adult failure to thrive as the principal diagnosis will be returned to the provider to resubmit with a more definitive principal diagnosis coding.

CMS first gave notice of this clarification in the proposed rule for FY 2014, published in the Federal Register on May 10, 2013 2. In doing so, CMS asserted that this was not a new proposal. Rather, CMS indicated that this clarification was merely being consistent with ICD-9-CM Coding Guidelines, which provide that “Symptoms, Signs, and Ill-defined Conditions,” including adult failure to thrive and debility, are not to be used as principal diagnoses. 3

CMS’s motivation for this clarification apparently was the changes in diagnosis patterns over the years. At the beginning of the hospice benefit in 1983, the most commonly reported principal diagnoses for hospice were cancer diagnoses. 4   Over time, non-cancer diagnoses have become more commonly reported. In 2002, adult failure to thrive and debility together accounted for 9% of the top 20 principal diagnoses. Ten years later, these two diagnoses were the first and third most commonly reported diagnoses, accounting for 19% of the top 20. 5   They thus captured the attention of CMS and lead to the clarification of policy.

CMS’s Justification for Policy Clarification

CMS’s primary justification for this clarification was concern that the use of non-specific diagnoses of adult failure to thrive and debility, without any other diagnoses, means that Medicare hospice beneficiaries are not being thoroughly assessed and therefor may not be receiving the full range of services the Medicare Hospice benefit envisioned.

More significantly, CMS expressed its concern that use of a non-specific diagnosis such as adult failure to thrive or debility indicates that the “multiple comorbid conditions” that accompany these diagnoses may not be adequately diagnosed, thereby depriving beneficiaries of an informed understanding of their condition and of all the possible options available to them. CMS believes this clarification will encourage hospices to be “more intentional about addressing all of the beneficiary’s identified needs” as the end of life approaches.

CMS acknowledges that, where a patient has multiple coexisting conditions, no one condition, individually, may deem the patient as terminally ill; however, the collective presence of them and the progressive nature of some of them will contribute to the terminal diagnosis. In such instances, CMS states that the physician should “select the condition he or she feels is most contributory to the terminal prognosis, based on information in the comprehensive assessment, other relevant clinical information supporting all diagnoses, and his or her best clinical judgment.”

Commenters questioned CMS’s concern with diagnoses, when hospice eligibility is based on the terminal prognosis of a patient, and not on diagnosis. CMS confirmed that hospice eligibility is based on a terminal prognosis. However, CMS pointed to the requirements for certifications and recertifications – that clinical information in the medical record must support the medical prognosis, and that the physician include a narrative of the clinical findings supporting the terminal diagnosis. CMS indicated that it is not seeing the level of completeness of diagnosis reporting as is required for the certifications and recertifications. Further, CMS stated that many hospices have been coding “a single terminal diagnosis” when eligibility “should always have been based on the terminal prognosis of the patient, and this prognosis would typically involve more than one diagnosis.”

CMS also discussed what conditions are “related” versus “unrelated” to the terminal illness by quoting the 1983 policy that “…hospices are required to provide virtually all the care that is needed by terminally ill patients.” CMS reiterated that “unless there is clear evidence that a condition is unrelated to the terminal prognosis, all services would be considered related. It is also the responsibility of the hospice physician to document why a patient’s medical need(s) would be unrelated to the terminal prognosis.”

Many of the commenters on the proposed rule expressed concern that this clarification would limit or prohibit access to hospice care for many Medicare beneficiaries. CMS denied this assertion, noting that certifications for hospice eligibility are based on prognosis, not diagnosis, and are completed no more than 15 days prior to the start of the benefit period. Diagnosis coding on the hospice claim form is not done until after the patient has been informed of his or her choices and accepted into hospice. Similarly, CMS rejected comments saying that this clarification was a change of coverage that should go through the National Coverage Determination process. CMS denied it was making any changes in coverage or eligibility policies but only making a coding clarification “to request more clarity and detail on the hospice claims to reflect a complete picture of the Medicare hospice population and the hospice services rendered.”

CMS supported its decision with an analysis showing that, in 2012, for those beneficiaries with adult failure to thrive or debility reported as the principal hospice diagnosis with no secondary diagnosis, over 50% of them had seven or more chronic conditions, and 75% of them had four or more chronic conditions. CMS noted that many of these chronic conditions are also terminal conditions, or contributory to the terminal prognosis. If multiple conditions are being treated, or if medications have been prescribed to treat or manage them, then CMS said it would be inappropriate to use adult failure to thrive or debility as a principle diagnosis.

As further justification, CMS indicated that it needs more complete diagnosis information on claims as it moves forward with hospice payment reform. Although the precise terms of hospice payment reform have not yet been proposed, CMS’s more immediate concern is the trend that some hospice-related drugs used for hospice patients are being charged to Medicare Part D, rather than being covered under the bundled payment of the hospice benefit, causing additional and inappropriate payments to be made. For example, CMS pointed out that nearly 15 percent of hospice patients in 2010 received analgesic prescriptions through Part D; in total Medicare hospice beneficiaries receives prescriptions under Part D totaling over $350,000,000. This echoes the concerns expressed in the OIG Report “Medicare Could be Paying Twice for Prescription Drugs for Beneficiaries in Hospice.”

In response to comments pointing out that many Local Coverage Determinations (LCDs) by Home Health and Hospice Medicare Administrative Contractors permitted the use of adult failure to thrive or debility as a primary diagnoses, CMS said it would be working with those contractors to ensure all LCDs will reflect these coding clarifications. CMS also noted that LCDs are used to determine eligibility for hospice services, and not to determine the appropriate diagnoses codes on hospice claims.

Although recognizing that this clarification would be a significant change for many hospices, CMS denied that this clarification would require hospices to hire professional coders and create a financial burden. CMS said the clarification was made to assist hospices in complying with longstanding coding policy that these two diagnoses should be reported as principal diagnoses, and pointed the hospices to several coding resources on the CMS website to assist them. CMS noted that the paper UC-04 forms have always had space to list up to 17 additional diagnosis fields, and the electronic claim form has up to 24 additional diagnosis fields.

Delayed Effective Date for Return of Claims to Provider

One positive outcome of the rulemaking process was CMS’s decision to delay the effective date of this clarification. It was unclear in the proposed rule whether this policy clarification would be applied retrospectively to claims already submitted, or whether it would have prospective effect. Indeed, some Medicare contractors began returning claims to providers prior to the end of the comment period. In the final rule, even though it characterized its statements about failure to thrive and debility as a clarification, CMS acknowledged that this clarification may be a “paradigm shift” for some hospices in the way they have coded claims. CMS therefore made the clarification effective for claims dated on or after October 1, 2014. As of that date, any claims submitted with adult failure to thrive or debility as the principal diagnosis will be returned to the provider for more definitive coding of the principal and additional diagnoses. CMS also expects, however, that hospices will “transition immediately to more thoughtful coding practices in advance of this effective date.

What Hospices Need to Do

  • Educate the staff and hospice physicians on this policy clarification:
    • Identify all conditions that contribute to the terminal prognosis.
    • The principal diagnosis should be the diagnosis most contributory to the terminal prognosis, and the one chiefly responsible for the services provided.
  • Make sure edits exist in the billing system to identify any claims where adult failure to thrive or debility are listed as the primary diagnosis, Where these are identified, work with the attending physician to determine if there is a more specific principal diagnosis contributing to the terminal prognosis.

NOTES

1 78 Fed. Reg. 48234.
2 78 Fed. Reg. 27823.
3 Id. at 27832.
4 Id.at 27831.
5 Id. at 27829.
6 78 Fed. Reg. at 48244
7 Id.
8 Id. at 48247.
9 Id. at 48248.
10 Id. at 48251.
11 Id. at 48252.
12 Id. at 48244.
13 Id. at 48245
14 Id. See also discussion of status of hospice payment reform at 78 Fed. Reg. 48271-75.
15 Id. at 48245-46. See OIG Report A-06-10-00059, June 2012, available at http://oig.hhs.gov/oas/reports/region6/61000059.pdf.
16 Id. at 48243.
17 Id. at 48247.
18 Id. at 48242.
19 Id. at 48250.
20 Id.
21 Id.at 48246.
22 Id.
23 Id. at 48252.

Copyright 2013, American Health Lawyers Association, Washington, DC. Reprint permission granted.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Baker Donelson | Attorney Advertising

Written by:

Baker Donelson
Contact
more
less

Baker Donelson on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!